Patient demographics and clinical characteristics based on best response
| Characteristic . | n (%) . |
|---|---|
| Sex | |
| Female | 13 (43) |
| Male | 17 (57) |
| Stage | |
| II | 4 (13) |
| III | 8 (27) |
| IV | 18 (60) |
| ECOG score | |
| 0 | 22 (73) |
| 1 | 8 (27) |
| FLIPI score | |
| 0-1 | 8 (27) |
| 2 | 16 (53) |
| 3-5 | 6 (20) |
| GELF assessment | |
| Low tumor burden | 15 (50) |
| High tumor burden | 15 (50) |
| Prior therapies, n | |
| 1 | 18 (60) |
| 2 | 6 (20) |
| ≥3 | 6 (20) |
| PFS with last therapy, y | |
| <1 | 5 (17) |
| >/=1 | 25 (83) |
| POD24 status, mo | |
| <24 | 11 (37) |
| >/=24 | 19 (63) |
| Characteristic . | n (%) . |
|---|---|
| Sex | |
| Female | 13 (43) |
| Male | 17 (57) |
| Stage | |
| II | 4 (13) |
| III | 8 (27) |
| IV | 18 (60) |
| ECOG score | |
| 0 | 22 (73) |
| 1 | 8 (27) |
| FLIPI score | |
| 0-1 | 8 (27) |
| 2 | 16 (53) |
| 3-5 | 6 (20) |
| GELF assessment | |
| Low tumor burden | 15 (50) |
| High tumor burden | 15 (50) |
| Prior therapies, n | |
| 1 | 18 (60) |
| 2 | 6 (20) |
| ≥3 | 6 (20) |
| PFS with last therapy, y | |
| <1 | 5 (17) |
| >/=1 | 25 (83) |
| POD24 status, mo | |
| <24 | 11 (37) |
| >/=24 | 19 (63) |
Data are expressed as the number (percentage of each group), unless the a of measure is otherwise noted.